Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments on how the transformation of the French healthcare system will impact the CEPS’s role in price negotiation.
You are often juxtaposing the utilitarian Anglo-Saxon model of drug pricing with the more universal French model. Can you tell us more about this comparison for our international audience?
This is quite a complicated matter. Many actors are under the “charm” of the Anglo-Saxon system. It has a certain mechanical rationality to it that renders it attractive. The system is primarily founded on the criteria of reimbursement.
President Macron’s plans will have an indirect impact on the CEPS, as they will undoubtedly cause a shift in the way that medical products, therapies and treatments are designed.
